Lancet (London, England)

Preventing muscle loss during weight loss with Trevogrumab alone or with Garetosmab in people with obesity

Updated

Abstract

Rapid weight loss induced by GLP-1 receptor agonists is associated with pronounced muscle loss.

  • GDF8 (myostatin) and activin A (ActA) are identified as negative regulators of muscle mass.
  • Antibodies that block GDF8 and ActA may have a role in counteracting muscle loss.
  • The study aims to evaluate the effects of two specific antibodies on weight and muscle loss during semaglutide treatment.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free